Alemtuzumab, IFN-gamma inhibitor (NI-0501), and Janus kinase 1 (JAK1)/JAK2 inhibitor (ruxolitinib) are novel therapeutic agents either in trials or approved for HLH treatment [1]. Here, IFNG is linked to hemophagocytic syndrome.